Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Collagen XIX Alpha 1 improves prognosis in amyotrophic lateral sclerosis

  • Calvo, Ana C.
  • Atencia Cibreiro, Gabriela
  • Torre Merino, Paz
  • Roy, Juan F.
  • Galiana, Adrián
  • Juárez Rufian, Alexandra
  • Cano, Juan M.
  • Martin, Miguel Ángel
  • Moreno, Laura
  • Larrodé, Pilar
  • Cordero Vázquez, Pilar
  • Galan, Lucía
  • Mora, Jesús
  • Muñoz-Blanco, José Luis
  • Muñoz, María J.
  • Zaragoza, Pilar
  • Pegoraro, Elena
  • Sorarú, Gianni
  • Mora, Marina
  • Lunetta, Christian
  • Penco, Silvana
  • Tarlarini, Claudia
  • Esteban, Jesús
  • Osta, Rosario
  • García Redondo, Alberto
The identification of more reliable diagnostic or prognostic biomarkers in age-related neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), is urgently needed. The objective in this study was to identify more reliable prognostic biomarkers of ALS mirroring neurodegeneration that could be of help in clinical trials. A total of 268 participants from three cohorts were included in this study. The muscle and blood cohorts were analyzed in two cross-sectional studies, while the serial blood cohort was analyzed in a longitudinal study at 6-monthly intervals. Fifteen target genes and fourteen proteins involved in muscle physiology and differentiation, metabolic processes and neuromuscular junction dismantlement were studied in the three cohorts. In the muscle biopsy cohort, the risk for a higher mortality in an ALS patient that showed high Collagen type XIX, alpha 1 (COL19A1) protein levels and a fast progression of the disease was 70.5% (P < 0.05), while in the blood cohort, this risk was 20% (P < 0.01). In the serial blood cohort, the linear mixed model analysis showed a significant association between increasing COL19A1 gene levels along disease progression and a faster progression during the follow-up period of 24 months (P < 0.05). Additionally, higher COL19A1 levels and a faster progression increased 17.9% the mortality risk (P < 0.01). We provide new evidence that COL19A1 can be considered a prognostic biomarker that could help the selection of homogeneous groups of patients for upcoming clinical trial and may be pointed out as a promising therapeutic target in ALS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1G93A ALS mice and after partial muscle denervation

  • Mancuso, Renzo
  • Martínez Muriana, Anna|||0000-0002-8645-1317
  • Leiva-Rodríguez, Tatiana|||0000-0003-0359-0045
  • Gregorio Martínez, David
  • Ariza, Lorena
  • Morell, Marta
  • Esteban-Pérez, Jesús
  • García-Redondo, Alberto
  • Calvo, Ana Cristina|||0000-0001-5193-7782
  • Atencia-Cibreiro, Gabriela
  • Corfas, Gabriel
  • Osta, Rosario|||0000-0001-5687-6704
  • Bosch i Merino, Assumpció|||0000-0002-7205-2796
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive degeneration of motoneurons, which is preceded by loss of neuromuscular connections in a "dying back" process. Neuregulin-1 (Nrg1) is a neurotrophic factor essential for the development and maintenance of neuromuscular junctions, and Nrg1 receptor ErbB4 loss-of-function mutations have been reported as causative for ALS. Our main goal was to investigate the role of Nrg1 type I (Nrg1-I) in SOD1G93A mice muscles. We overexpressed Nrg1-I by means of an adeno-associated viral (AAV) vector, and investigated its effect by means of neurophysiological techniques assessing neuromuscular function, as well as molecular approaches (RT-PCR, western blot, immunohistochemistry, ELISA) to determine the mechanisms underlying Nrg1-I action. AAV-Nrg1-I intramuscular administration promoted motor axon collateral sprouting by acting on terminal Schwann cells, preventing denervation of the injected muscles through Akt and ERK1/2 pathways. We further used a model of muscle partial denervation by transecting the L4 spinal nerve. AAV-Nrg1-I intramuscular injection enhanced muscle reinnervation by collateral sprouting, whereas administration of lapatinib (ErbB receptor inhibitor) completely blocked it. We demonstrated that Nrg1-I plays a crucial role in the collateral reinnervation process, opening a new window for developing novel ALS therapies for functional recovery rather than preservation.